ALNYLAM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALNYLAM
ALNYLAM has four approved drugs.
There are forty US patents protecting ALNYLAM drugs.
There are six hundred and ninety-seven patent family members on ALNYLAM drugs in fifty-two countries and ninety-two supplementary protection certificates in eighteen countries.
Summary for ALNYLAM
| International Patents: | 697 |
| US Patents: | 40 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for ALNYLAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 11,261,447 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | 10,570,391 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | 10,806,791 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALNYLAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 11,530,408 | ⤷ Start Trial |
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 9,150,605 | ⤷ Start Trial |
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 9,943,539 | ⤷ Start Trial |
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,372,968 | ⤷ Start Trial |
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,334,373 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALNYLAM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 622843 | ⤷ Start Trial |
| Denmark | 2344639 | ⤷ Start Trial |
| China | 113599389 | ⤷ Start Trial |
| Australia | 2019240658 | ⤷ Start Trial |
| Japan | 2019022519 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALNYLAM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3052628 | SPC/GB20/042 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: GIVOSIRAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/20/1428 (NI) 20200304; UK PLGB 50597/0004 20200304 |
| 3204015 | 834 | Finland | ⤷ Start Trial | |
| 2937418 | SPC/GB19/005 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: PATISIRAN; REGISTERED: UK EU/1/18/1320(FOR NI) 20180827; UK PLGB 50597/0002 20180827 |
| 3204015 | 202240010 | Slovenia | ⤷ Start Trial | PRODUCT NAME: LUMASIRAN; NATIONAL AUTHORISATION NUMBER: EU/1/20/1496/001; DATE OF NATIONAL AUTHORISATION: 20201119; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 3581654 | 38/2021 | Austria | ⤷ Start Trial | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 (MITTEILUNG) 20201123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
